Hyaluronic acid-coated and Olaparib-loaded PEI - PLGA nanoparticles for the targeted therapy of triple negative breast cancer

Aim To prepare the hyaluronic acid-coated Olaparib-loaded PEI - PLGA nanoparticles (HA-Ola-PPNPs) and investigate their tumour-targeted anticancer effect. Methods The synthesis of HA-Ola-PPNPs was verified by DLS, TEM and SEM, followed was measured its cytotoxicity using CCK-8 assay. Confocal microscopy was used to observe the cellular uptake. Cell apoptosis was analysed by flow cytometry, biological SEM, and TEM. The expression of related proteins within the tumour site was investigated by immunostaining. Results The prepared HA-Ola-PPNPs showed a diameter of similar to 160 nm with a negatively charged surface (-16.9 +/- 2.7 mV) and sustained drug release behaviour. And the encapsulation efficiency of HA-Ola-PPNPs was 78.63 +/- 5.29%. HA-Ola-PPNPs exhibited efficient in vitro and in vivo antitumor activities. HA-Ola-PPNPs induced cell apoptosis by upregulating Bax, Cytochrome C, and Caspase 3, downregulating Bcl-2 in breast cancer-bearing mice. Conclusions According to the results, the Ola-loaded and HA-coated PEI - PLGA nanoparticles could be considered as a powerful tumour-targeted drug delivery system for TNBC treatment.

Automated summary

The study prepared hyaluronic acid-coated Olaparib-loaded PEI-PLGA nanoparticles and found that they exhibited efficient anticancer activity in vitro and in vivo. The nanoparticles induced cell apoptosis to inhibit breast cancer growth by upregulating Bax, Cytochrome C, and Caspase 3, and downregulating Bcl-2, suggesting their potential as a tumor-targeted drug delivery system for triple-negative breast cancer treatment.